GlassScriptPhysician profile
George H Limpert
NPI 1467411694
$4,243.93
in general payments reported to CMS, 2019-2025
46 companies · $31.85 in 2025
The $31.85 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $770 · 2020: $567 · 2021: $529 · 2022: $629 · 2023: $950 · 2024: $766 · 2025: $31.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,747.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $520.01 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $474.74 | 2019-2024 | Farxiga, Breztri, Fasenra |
| Pfizer INC. | $462.66 | 2019-2024 | |
| Abbvie INC. | $410.64 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $318.85 | 2019-2024 | Jardiance |
| Glaxosmithkline, LLC. | $260.96 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $138.10 | 2019-2024 | Veozah, Myrbetriq |
| Lilly USA, LLC | $119.05 | 2019-2024 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $113.65 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $91.88 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $88.90 | 2020-2023 | Rexulti |
| Abbott Laboratories | $84.97 | 2022-2024 | Octrode, Freestyle Libre 2, Freestyle Libre 3 |
| Corium, LLC | $79.76 | 2022-2024 | Azstarys |
| Novartis Pharmaceuticals Corporation | $72.09 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $66.99 | 2019-2020 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Limpert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.